Silence Therapeutics
NASDAQ: SLNLondon · United Kingdom corporation · 4 known investors
Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
Founders & leadership
JE
James Ede-GolightlyNamed on SEC filing
AG
Alistair GrayNamed on SEC filing
CT
Craig ToomanNamed on SEC filing
DL
Dave LemusNamed on SEC filing
GC
Giles CampionNamed on SEC filing
RS
Romano StevenNamed on SEC filing
MH
Michael H. DavidsonNamed on SEC filing
MR
Mark RotheraNamed on SEC filing
IR
Iain RossNamed on SEC filing
BR
Barbara RuskinNamed on SEC filing
Investors · 4
Reported raises · per SEC filings
Form D private placements$45.5M disclosed across 1 round · 2021
▶$45.5MraisedFeb 2021 · 12 investors · BiotechnologyRule 506(b)
▶$45.5MraisedFeb 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James Ede-GolightlyDirector
- Alistair GrayDirector
- Craig ToomanExecutive Officer
- Dave LemusDirector
- Giles CampionExecutive Officer
- Romano StevenDirector
- Michael H. DavidsonDirector
- Mark RotheraExecutive Officer, Director
- Iain RossDirector
- Barbara RuskinExecutive Officer
- Offering amount
- $45.5M
- Amount sold
- $45.5M
- Sales commissions
- $2.7M
- Placement agents
- William Blair & Company, L.L.C.
- First sale
- Feb 2021
- Incorporated
- Corporation, United Kingdom
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Acquisitions · 1
Early investors' stakes continue via these dealsIntradigm Corporation
Developed RNAi therapeutics; merged with Silence Therapeutics in December 2009.
Frequently asked questions
- What does Silence Therapeutics do?
- Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.
- Who are Silence Therapeutics's investors?
- Silence Therapeutics's investors include Foresite Capital, MC Healthcare Ventures, Nextech Invest, Vivo Capital.
- How much funding has Silence Therapeutics raised?
- Silence Therapeutics has disclosed $45.5M raised across 1 round.
- Where is Silence Therapeutics headquartered?
- Silence Therapeutics is headquartered in London.